Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dancing with atrial fibrillation - How arrhythmia affects everyday life of family members: A qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Insulin resistance genetic risk score and burden of coronary artery disease in patients referred for coronary angiography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Danish guidelines for management of non-APC-associated hereditary polyposis syndromes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence of Pathogenic Germline DICER1 Variants in Young Individuals Thyroidectomised Due to Goitre - A National Danish Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: TP53 mutation carrier (Li-Fraumeni Syndrome, LFS) cohort studies often suffer from lack of extensive pedigree exploration.

METHODS: We performed a nation-wide exploration of TP53 mutation carrier families identified through all clinical genetics departments in Denmark. Pedigrees were expanded and verified using unique national person identification, cancer, cause of death, pathology, and church registries.

RESULTS: We identified 30 confirmed, six obligate and 14 assumed carriers in 15 families harboring 14 different mutations, including five novel and three de novo germline mutations. All but two (96%) developed cancer by age 54 years [mean debut age; 29.1 y., median 33.0 y., n = 26 (17F, 9M), range 1-54 y]]. Cancer was the primary cause of all deaths [average age at death; 34.5 years]. Two tumors were identified through registry data alone. Two independent families harbored novel c.80delC mutations shown to be related through an ancestor born in 1907. This exhaustive national collection yielded markedly fewer TP53 mutation carriers than the 300-1,100 expected based on estimated background population frequencies.

CONCLUSION: Germline TP53 mutations in Denmark are likely to be drastically underdiagnosed despite their severe phenotype. Following recent advances in surveillance options of LFS patients, lack of pre-symptomatic testing may lead to the mismanagement of some individuals.

OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind13
Udgave nummer1
Sider (fra-til)e0190050
ISSN1932-6203
DOI
StatusUdgivet - 2018

ID: 52408562